EWTX
Income statement / Annual
Last year (2025), Edgewise Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Edgewise Therapeutics Inc's net income was -$167.80 M.
See Edgewise Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$2.27 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$185.00 K
|
$123.00 K
|
| Gross Profit |
-$2.27 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$185.00 K
|
-$123.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$151.39 M
|
$126.97 M
|
$90.91 M
|
$54.03 M
|
$32.19 M
|
$14.80 M
|
$8.62 M
|
| General & Administrative Expenses |
$40.02 M
|
$31.87 M
|
$23.45 M
|
$17.63 M
|
$11.03 M
|
$2.21 M
|
$1.30 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$40.02 M
|
$31.87 M
|
$23.45 M
|
$17.63 M
|
$11.03 M
|
$2.21 M
|
$1.30 M
|
| Other Expenses |
-$2.27 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$189.14 M
|
$158.83 M
|
$114.36 M
|
$71.66 M
|
$43.22 M
|
$17.01 M
|
$9.92 M
|
| Cost And Expenses |
$191.41 M
|
$158.83 M
|
$114.36 M
|
$71.66 M
|
$43.22 M
|
$17.19 M
|
$9.92 M
|
| Interest Income |
$23.61 M
|
$25.02 M
|
$14.19 M
|
$2.66 M
|
$402.00 K
|
$69.00 K
|
$219.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$4.02 M
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$2.27 M
|
$2.29 M
|
$1.73 M
|
$538.00 K
|
$272.00 K
|
$185.00 K
|
$123.00 K
|
| EBITDA |
-$165.53 M |
-$156.54 M |
-$112.63 M |
-$71.12 M |
-$42.94 M |
-$17.01 M |
-$9.80 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$23.61 M
|
$25.02 M
|
$14.19 M
|
$4.02 M
|
$402.00 K
|
$69.00 K
|
$219.00 K
|
| Income Before Tax |
-$167.80 M
|
-$133.81 M
|
-$100.16 M
|
-$67.64 M
|
-$42.81 M
|
-$17.12 M
|
-$9.71 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$167.80 M
|
-$133.81 M
|
-$100.16 M
|
-$67.64 M
|
-$42.81 M
|
-$17.05 M
|
-$9.49 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.63 |
-1.45 |
-1.57 |
-1.26 |
-0.86 |
-0.35 |
-0.19 |
| EPS Diluted |
-1.63 |
-1.45 |
-1.57 |
-1.26 |
-0.86 |
-0.35 |
-0.19 |
| Weighted Average Shares Out |
$102.93 M
|
$92.41 M
|
$63.72 M
|
$53.59 M
|
$49.50 M
|
$49.22 M
|
$49.22 M
|
| Weighted Average Shares Out Diluted |
$102.93 M
|
$92.41 M
|
$63.72 M
|
$53.59 M
|
$49.50 M
|
$49.22 M
|
$49.22 M
|
| Link |
|
|
|
|
|
|
|
